Laboratorios Farmaceuticos ROVI SA banner

Laboratorios Farmaceuticos ROVI SA
MAD:ROVI

Watchlist Manager
Laboratorios Farmaceuticos ROVI SA Logo
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Watchlist
Price: 79.15 EUR -0.69%
Market Cap: €4.1B

P/B

6.1
Current
14%
More Expensive
vs 3-y average of 5.4

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
6.1
=
Market Cap
€4.1B
/
Total Equity
€664.4m

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
6.1
=
Market Cap
€4.1B
/
Total Equity
€664.4m

Valuation Scenarios

Laboratorios Farmaceuticos ROVI SA is trading above its 3-year average

If P/B returns to its 3-Year Average (5.4), the stock would be worth €69.55 (12% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-68%
Maximum Upside
No Upside Scenarios
Average Downside
36%
Scenario P/B Value Implied Price Upside/Downside
Current Multiple 6.1 €79.15
0%
3-Year Average 5.4 €69.55
-12%
5-Year Average 6.1 €79.06
0%
Industry Average 2.2 €28.38
-64%
Country Average 2 €25.41
-68%

Forward P/B
Today’s price vs future total equity

Not enough data available to calculate forward P/B

Peer Comparison

All Multiples
P/B
P/E
All Countries
Close
Market Cap P/B P/E
ES
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
4.1B EUR 6.1 28.8
US
Eli Lilly and Co
NYSE:LLY
825.8B USD 31.1 40
US
Johnson & Johnson
NYSE:JNJ
548.5B USD 6.7 26.1
CH
Roche Holding AG
SIX:ROG
248.4B CHF 7.7 20.1
UK
AstraZeneca PLC
LSE:AZN
215.6B GBP 5.8 27.4
CH
Novartis AG
SIX:NOVN
220.1B CHF 5.9 19.5
US
Merck & Co Inc
NYSE:MRK
272.3B USD 5.2 14.9
IE
Endo International PLC
LSE:0Y5F
244.4B USD -58.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 6 11.4
US
Pfizer Inc
NYSE:PFE
150.6B USD 1.7 19.4
US
Bristol-Myers Squibb Co
NYSE:BMY
117.3B USD 6.3 16.6
P/E Multiple
Earnings Growth PEG
ES
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Average P/E: 22.4
28.8
22%
1.3
US
Eli Lilly and Co
NYSE:LLY
40
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.1
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
14.9
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.4
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.6
16%
1

Market Distribution

Higher than 89% of companies in Spain
Percentile
89th
Based on 667 companies
89th percentile
6.1
Low
0.4 — 1.4
Typical Range
1.4 — 2.9
High
2.9 —
Distribution Statistics
Spain
Min 0.4
30th Percentile 1.4
Median 2
70th Percentile 2.9
Max 56.2

Laboratorios Farmaceuticos ROVI SA
Glance View

Laboratorios Farmacéuticos ROVI SA has carved a niche for itself in the pharmaceutical industry through its focus on researching, developing, manufacturing, and marketing a broad range of small molecule drugs and specialized products. Founded in Spain, ROVI has channeled its efforts towards creating innovative solutions in the healthcare sector, with heparin-based products emerging as a cornerstone of its portfolio. The company's operational model is built on vertical integration, allowing it to control the entire lifecycle of its offerings, from production to commercialization. This approach not only ensures quality and compliance with stringent regulatory standards but also enables ROVI to adapt nimbly to market demands and leverage its proprietary science to secure a competitive edge. The revenue streams of ROVI are diversified across its proprietary products, contract manufacturing services, and its portfolio of licensed products. A significant portion of revenue stems from its commitment to injectable drug products like Bemiparin, a low molecular weight heparin, which has found a foothold in various international markets. Moreover, ROVI capitalizes on partnerships and alliances with major pharmaceutical giants, augmenting its contract manufacturing capabilities and tapping into more extensive distribution networks. Not resting on its laurels, ROVI invests heavily in research and development to fortify its pipeline with innovative formulations, thus ensuring sustained growth and a resilient positioning in the global pharmaceutical landscape. This blend of strategic partnerships, internal innovation, and market-responsive production underscores ROVI's business model and revenue generation prowess.

ROVI Intrinsic Value
69.81 EUR
Overvaluation 12%
Intrinsic Value
Price €79.15
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett